A multi-laboratory evaluation of an enzyme-linked immunoassay quantitating human antibodies to streptococcus pneumoniae polysaccharides

Immunological Investigations

Volumn 30, Issue 3, 2001, Pages 191-207

  Quataert, S ^a   Martin, D ^a   Anderson, P ^a   Giebink, G S ^a   Henrichsen, J ^a   Leinonen, M ^a   Granoff, D M ^a   Russell, H ^a   Siber, G ^a   Faden, H ^a   Barnes, D ^a   Madore, D V ^a  

^a Wyeth Lederle Vaccines   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BACTERIAL POLYSACCHARIDE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PNEUMOCOCCUS VACCINE;

ANTIBODY BLOOD LEVEL; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOASSAY; LABORATORY TEST; MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; SEROTYPE; STANDARDIZATION; STREPTOCOCCUS PNEUMONIAE;

ENZYME-LINKED IMMUNOSORBENT ASSAY; EVALUATION STUDIES; HUMANS; IMMUNE SERA; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; IMMUNOGLOBULIN M; LABORATORIES; POLYSACCHARIDES, BACTERIAL; REPRODUCIBILITY OF RESULTS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

EID: 0034851882     PISSN: 08820139     EISSN: None     Source Type: Journal    
DOI: 10.1081/IMM-100105064     Document Type: Article

References (47)

1. First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants
2. Pneumococcal disease: Prospects for a new generation of vaccines
3. Distribution of serotypes of streptococcus pneumoniae isolated from invasive infections over a 16-year period in the greater Sao Paulo area, Brazil
4. Pathogenesis of pneumococcal infection
5. Serotypes responsible for invasive streptococcus pneumoniae infections among children in Connecticut
6. Epidemiological studies of streptococcus pneumoniae in infants: Antibody to types 3, 6, 14, and 23 in the first two years of life
7. Serotypes of streptococcus pneumoniae causing disease
8. Increasing prevalence of penicillin-resistant pneumococcal infections in children in southern Isreal: Implications for future immunization policies
9. Antibiotic resistance in streptococcus pneumoniae
10. A global gene pool for high-level cephalosporin resistance in commensal streptococcus species and streptococcus pneumoniae
11. IBS department. Modern approaches to new vaccines including prevention of aids
12. Epidemiology of invasive childhood pneumococcal infections in Israel
13. Bacteremic pneumococcal infections in Connecticut children from 1984-1992
14. Epidemiology of invasive pneumococcal infections in children in Finland
15. The contribution of specific pneumococcal serogroups to different disease manifestations: Implications for conjugate vaccine formulation and use, Part II
16. Three-year multicenter surveillance of systemic pneumococcal infections in children
17. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infections?
18. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people
19. Pneumococcal vaccination in the United States and 20 other developed countries, 1981-1996
20. Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in pre-school age children
21. 197 conjugate vaccine in 1- to 6-month-old infants
22. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive haemophilus influenzae type B disease
23. Safety and immunogenicity of oligosaccharide conjugate haemophilus influenzae type B (HbOC) vaccine in infancy
24. 197 in United States infants
25. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
26. 197 conjugate vaccine in infants and toddlers
27. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children
28. Safety and immunogenicity of a 5-valent conjugate pneumococcal vaccine (cpv) in HIV (+) and Non-HIV infected (-) children
29. Safety and immunogenicity of pentavalent S. pneumoniae (SPn) conjugate vaccines in healthy adults
30. Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines
31. 197 in United States infants
32. A randomized comparison of three bivalent streptococcus pneumoniae glycoprotein conjugate vaccines in young children: Effect of polysaccharide size and linkage characteristics
33. Antibody titers eight months after three doses of a five-valent pneumococcal conjugate vaccine in HIV and non-HIV-infected children less than two years of age
34. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine
35. Safety and immunogenicity of heptavalent pneumococcal conjugate vaccine (Wyeth-Lederle) in infancy
36. Safety and immunogenicity of heptavalent pneumococcal conjugate vaccine (Wyeth-Lederle)
37. 197 conjugate vaccine in infants and toddlers
38. 197 conjugate vaccine
39. Standardization and validation of immune responses with a pneumococcal IgG ELISA and data analysis for the evaluation of vaccine immunogenicity
40. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S
41. C-polysaccharide in a pneumococcal vaccine
42. Anti-C-carbohydrate antibodies after pneumococcal vaccination
43. The chemical composition of pneumococcal C-polysaccharide
44. Interlaboratory study evaluating quantitation of antibodies to haemophilus influenzae type B polysaccharide by enzyme-linked immunosorbent assay
45. Multicenter comparison of levels of antibody to the neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay
46. Multicenter comparison of neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay
47. An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study